Trial Profile

A Phase 1, Double-blind, Randomized, Placebo-controlled Study to Assess the Antiviral Activity and Safety of AT-752 in a Dengue Human Challenge Model

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 24 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AT 752 (Primary)
Indications Dengue
Focus Pharmacokinetics
Sponsors Atea Pharmaceuticals

Most Recent Events

20 Apr 2023 Status changed from active, no longer recruiting to discontinued (Sponsor decision to deprioritize the dengue program).
09 Jan 2023 According to an Atea pharmaceuticals media release, patient enrollment has been completed in this study. Analysis of data from this study is ongoing
09 Jan 2023 Status changed from recruiting to active, no longer recruiting, according to an Atea pharmaceuticals media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com